ES2754264T3 - Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K - Google Patents
Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K Download PDFInfo
- Publication number
- ES2754264T3 ES2754264T3 ES15810067T ES15810067T ES2754264T3 ES 2754264 T3 ES2754264 T3 ES 2754264T3 ES 15810067 T ES15810067 T ES 15810067T ES 15810067 T ES15810067 T ES 15810067T ES 2754264 T3 ES2754264 T3 ES 2754264T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- cyclohydrocarbyl
- heterocyclohydrocarbyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QRKOBESRHNBAQK-UHFFFAOYSA-N CN(C)CCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O Chemical compound CN(C)CCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O QRKOBESRHNBAQK-UHFFFAOYSA-N 0.000 description 1
- HDXVTQVEQTVENE-UHFFFAOYSA-N CNCCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O Chemical compound CNCCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O HDXVTQVEQTVENE-UHFFFAOYSA-N 0.000 description 1
- RPSTYXAPROLDNX-UHFFFAOYSA-N COc(c(NC(Nc(ccc(F)c1)c1Cl)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O Chemical compound COc(c(NC(Nc(ccc(F)c1)c1Cl)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O RPSTYXAPROLDNX-UHFFFAOYSA-N 0.000 description 1
- JDFFQWXREVXEFQ-UHFFFAOYSA-N COc(c(NC(c(c(Cl)c1)ccc1F)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O Chemical compound COc(c(NC(c(c(Cl)c1)ccc1F)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O JDFFQWXREVXEFQ-UHFFFAOYSA-N 0.000 description 1
- KYULFPRHBKJVCA-UHFFFAOYSA-N COc(c(NS(c(ccc(F)c1)c1Cl)(=O)=O)c1)ncc1C(C=CC1=NC(OCCN2CCOCC2)=C2)=CN1C2=O Chemical compound COc(c(NS(c(ccc(F)c1)c1Cl)(=O)=O)c1)ncc1C(C=CC1=NC(OCCN2CCOCC2)=C2)=CN1C2=O KYULFPRHBKJVCA-UHFFFAOYSA-N 0.000 description 1
- LCRFGZIUACFCTI-UHFFFAOYSA-N Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN(C)C)=CN2C3=O)cnc1OC)(=O)=O Chemical compound Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN(C)C)=CN2C3=O)cnc1OC)(=O)=O LCRFGZIUACFCTI-UHFFFAOYSA-N 0.000 description 1
- PSQHTFAFDLVSMZ-UHFFFAOYSA-N Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN4CCOCC4)=CN2C3=O)cnc1OC)(=O)=O Chemical compound Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN4CCOCC4)=CN2C3=O)cnc1OC)(=O)=O PSQHTFAFDLVSMZ-UHFFFAOYSA-N 0.000 description 1
- LEQKWADCYQGLKQ-UHFFFAOYSA-N Cc1c(C(Nc(cc(cn2)C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)c2OC)=O)[s]c(C)n1 Chemical compound Cc1c(C(Nc(cc(cn2)C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)c2OC)=O)[s]c(C)n1 LEQKWADCYQGLKQ-UHFFFAOYSA-N 0.000 description 1
- QYSPXCPOYOVSAP-UHFFFAOYSA-N Cc1c(NC(Nc2cc(C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)cnc2OC)=O)[s]c(C)n1 Chemical compound Cc1c(NC(Nc2cc(C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)cnc2OC)=O)[s]c(C)n1 QYSPXCPOYOVSAP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410271282.9A CN105461711B (zh) | 2014-06-17 | 2014-06-17 | 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| CN201510324348 | 2015-06-12 | ||
| PCT/CN2015/081518 WO2015192760A1 (zh) | 2014-06-17 | 2015-06-16 | 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2754264T3 true ES2754264T3 (es) | 2020-04-16 |
Family
ID=54934872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15810067T Active ES2754264T3 (es) | 2014-06-17 | 2015-06-16 | Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9856256B2 (enExample) |
| EP (1) | EP3159341B8 (enExample) |
| JP (1) | JP6680774B2 (enExample) |
| KR (1) | KR102495840B1 (enExample) |
| CN (1) | CN106470992B (enExample) |
| AU (1) | AU2015276699B2 (enExample) |
| CA (1) | CA2951971C (enExample) |
| EA (1) | EA032642B1 (enExample) |
| ES (1) | ES2754264T3 (enExample) |
| TW (1) | TWI628180B (enExample) |
| WO (1) | WO2015192760A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7037483B2 (ja) * | 2015-12-16 | 2022-03-16 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ピリド［１，２－ａ］ピリミドン類似体、それらの結晶形、それらの中間体、及びそれらの製造方法 |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| JP7331116B2 (ja) * | 2019-01-24 | 2023-08-22 | チアンスー アオサイカン ファーマシューティカル カンパニー，リミティド | ＴＧＦ－βＲ１キナーゼ阻害剤としての５－（４－ピリジルオキシ）ピラゾール類化合物 |
| BR112022010561A2 (pt) | 2019-12-02 | 2022-11-16 | Storm Therapeutics Ltd | Compostos poli-heterocíclicos como inibidores de mettl3 |
| CN115003674A (zh) | 2020-02-10 | 2022-09-02 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途 |
| CN115135649A (zh) * | 2020-03-10 | 2022-09-30 | 正大天晴药业集团股份有限公司 | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 |
| CA3194730A1 (en) * | 2020-09-15 | 2022-03-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma |
| CN116761608A (zh) * | 2020-12-08 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途 |
| WO2023169488A1 (zh) * | 2022-03-09 | 2023-09-14 | 正大天晴药业集团股份有限公司 | 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2541832C (en) * | 2003-10-10 | 2009-11-24 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
| EP2038272B8 (en) * | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| US20100311736A1 (en) * | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
| MX315904B (es) * | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| KR101911560B1 (ko) * | 2010-07-02 | 2018-10-24 | 길리애드 사이언시즈, 인코포레이티드 | 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물 |
| WO2012037108A1 (en) * | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| WO2013071698A1 (zh) * | 2011-11-17 | 2013-05-23 | 山东轩竹医药科技有限公司 | 三环类PI3K和/或mTOR抑制剂 |
| CN103539777B (zh) | 2012-07-13 | 2016-03-02 | 广东东阳光药业有限公司 | Pi3激酶调节剂及其使用方法和用途 |
| WO2014022128A1 (en) * | 2012-07-29 | 2014-02-06 | Calitor Sciences, Llc | Pi3 kinase modulators and methods of use |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP3159342B1 (en) * | 2014-06-17 | 2020-08-05 | Cisen Pharmaceutical Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor |
-
2015
- 2015-06-16 US US15/319,726 patent/US9856256B2/en active Active
- 2015-06-16 WO PCT/CN2015/081518 patent/WO2015192760A1/zh not_active Ceased
- 2015-06-16 CA CA2951971A patent/CA2951971C/en active Active
- 2015-06-16 KR KR1020177000523A patent/KR102495840B1/ko active Active
- 2015-06-16 CN CN201580027396.1A patent/CN106470992B/zh active Active
- 2015-06-16 JP JP2017518397A patent/JP6680774B2/ja active Active
- 2015-06-16 ES ES15810067T patent/ES2754264T3/es active Active
- 2015-06-16 EP EP15810067.7A patent/EP3159341B8/en active Active
- 2015-06-16 EA EA201790016A patent/EA032642B1/ru not_active IP Right Cessation
- 2015-06-16 AU AU2015276699A patent/AU2015276699B2/en active Active
- 2015-06-17 TW TW104119646A patent/TWI628180B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017519821A (ja) | 2017-07-20 |
| CN106470992A (zh) | 2017-03-01 |
| CN106470992B (zh) | 2018-11-06 |
| EP3159341B8 (en) | 2020-01-08 |
| CA2951971C (en) | 2024-09-10 |
| US9856256B2 (en) | 2018-01-02 |
| EA201790016A1 (ru) | 2017-06-30 |
| US20170137420A1 (en) | 2017-05-18 |
| TWI628180B (zh) | 2018-07-01 |
| AU2015276699B2 (en) | 2019-10-10 |
| EA032642B1 (ru) | 2019-06-28 |
| EP3159341B1 (en) | 2019-08-21 |
| AU2015276699A1 (en) | 2017-01-19 |
| WO2015192760A1 (zh) | 2015-12-23 |
| CA2951971A1 (en) | 2015-12-23 |
| EP3159341A1 (en) | 2017-04-26 |
| JP6680774B2 (ja) | 2020-04-15 |
| EP3159341A4 (en) | 2018-05-16 |
| KR20170016465A (ko) | 2017-02-13 |
| KR102495840B1 (ko) | 2023-02-03 |
| TW201625612A (zh) | 2016-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2754264T3 (es) | Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K | |
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| GT201300291A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias. | |
| AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| AR101177A1 (es) | Inhibidores de la syk | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| AR099970A1 (es) | Amidas, carbamatos y ureas que contienen carbazol como moduladores de criptocromo | |
| MX2018012609A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| PE20151592A1 (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia | |
| AR103934A1 (es) | Derivados de benzimidazoles como inhibidores de bromodominio | |
| PE20170327A1 (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| CO6420344A2 (es) | Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map) | |
| ECSP16090804A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| CR20190106A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres |